Varicella-zoster vaccine in the USA: Success for control of disease severity, but what next?

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 1, 2005, Pages 105-115

  Watson, Barbara ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Live attenuated; Oka Merck; Vaccine; Varicella; Varilrix ; Varivax

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GELATIN; GLUTAMIC ACID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; PHOSPHATE; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; SUCROSE; VARICELLA ZOSTER VACCINE;

BACTERIAL INFECTION; CELLULITIS; CHICKENPOX; CLINICAL TRIAL; DEHYDRATION; DIPHTHERIA; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HEALTH CARE POLICY; HEPATITIS B; HERPES ZOSTER; HOSPITALIZATION; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION CONTROL; INFLUENZA; INJECTION SITE; MEASLES; MUMPS; PARESTHESIA; PERTUSSIS; POLIOMYELITIS; PREGNANCY; REVIEW; RUBELLA; SINGLE DRUG DOSE; SKIN INFECTION; SKIN MANIFESTATION; SOFT TISSUE INFECTION; STREPTOCOCCUS INFECTION; TETANUS; THROMBOCYTOPENIA; UNITED STATES;

CHICKENPOX; CHICKENPOX VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; MASS IMMUNIZATION; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 14044271512     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.1.105     Document Type: Review

References (75)

1. Meyer P, Seward J, Jumaan A, Wharton M. Varicella mortality: trends before vaccine licensure in the USA. J. Infect. Dis. 182(2), 383-390 (2000).
2. Seward JF, Watson BM, Peterson CL et al. Varicella disease after introduction of varicella vaccine in the USA. J. Am. Med. Assoc. 287(5), 606-644 (2002).
3. Wharton M. The epidemiology of varicella-zoster virus infections. Infect. Dis. Clin. North Am. 10(3), 571-581 (1996).
4. Galil K, Lin F, Seward J. Hospitalizations for varicella in the USA. Pediatric Academic Societies and American Academy of Pediatrics Joint Meeting. Boston, MA, USA, 12-16 May 2000 (Abstract 1542).
5. Varivax®, package insert. Merck & Co. Inc., PA, USA.
6. Centers for Disease Control and Prevention. Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly Rep. 45(RR-11), 1-36 (1996).
7. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the use of live-attenuated varicella vaccine. Pediatrics 95(5), 791-796 (1995).
8. Centers for Disease Control and Prevention. Prevention of varicella. Morb. Mortal. Wkly Rep. 48(RR-6), 1-5 (1999).
9. American Academy of Pediatrics Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 105 (Pt 1), 136-141 (2000).
10. Varilrix®, package insert, GlaxoSmithKline, UK.
11. Quinlivan ML, Gershon AA, Steinberg SP, Breuer J. Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J. Infect. Dis. 190(4), 793-796 (2004).
12. Kuter BJ, Weibel RE, Guess HA et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9(9), 643-647 (1991).
13. Weibel RE, Neff BJ, Kuter BJ et al. Live-attenuated varicella virus vaccine. Efficacy trial in healthy children. N. Engl. J. Med. 310 (22), 1409 (1984).
14. White CJ, Kuter BJ, Hildebrand CS et al. Varicella vaccine (VArivax) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 87(5), 604-610 (1991).
15. White CJ, Kuter BJ, Ngai A et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antitbody response. Pediatr. Infect. Dis. J. 11(1), 19-23 (1992).
16. Kuter B, Matthews H, Shinefield H et al., and the Study Group for Varivax. 10-year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr. Infect. Dis. J. 23(2), 132-137 (2004).
17. Kuter BJ, Ngai A, Patterson CM et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine 13(11), 967-972 (1995).
18. Clements DA, Zaref JI, Bland CL, Walter EB, Coplan P. Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 daycare centers in North Carolina. Arch. Pediatr. Adolesc. Med. 155(4), 455-461 (2001).
19. Vazquez M, LaRussa P, Gershon A, Steinberg S, Freudigman K, Shapiro E. The effectiveness of the varicella vaccine in clinical practice. N. Engl. J. Med. 344(13), 955-960 (2001).
20. Vazquez M, LaRussa P, Gershon AA et al. Effectiveness over time of varicella vaccine. J. Am. Med. Assoc. 291(7), 851-855 (2004).
21. Watson B, Piercy S, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck Varicella vaccine. Pediatrics 91(1), 17-22 (1993).
22. LaRussa P, Steinberg S, Meurice F, Gershon A. Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts. J. Infect. Dis. 176(4), 1072-1075 (1997).
23. Sharrar RG, LaRussa P, Galea S et al. The postmarketing safety profile of varicella vaccine. Vaccine 19(7-8), 916-923 (2000).
24. Gershon AA. Varicella vaccine. Isr. J. Med. Sci. 19(11), 1024-1025 (1983).
25. Taylor JA, Newman RD. Parental attitudes toward varicella vaccination. The Puget Sound Pediatric Research Network. Arch. Pediatr. Adolesc. Med. 154(3), 302-306 (2000).
26. Mulholland M, Lutz J. Vaccine storage issues - Philadelphia vaccines for children program. CDC Immunization Program Managers Meeting. March 2001.
27. Shapiro ED, LaRussa PS. Vaccination for varicella - just do it! J. Am. Med. Assoc. 278(18), 1529-1530 (1997).
28. Chew D, Hoffman J, O'Donnel C, Finelli L. Physician attitudes and practices regarding varicella vaccine in New Jersey. Proqram and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, USA, 15-18 September 1996 (Abstract K158).
29. National, state and urban area vaccination Coverage levels among children aged 19-35 months - USA, Morb. Mortal. Wkly Rep. 50(30), 637-641 (2001).
30. Plotkin SA. Varicella vaccine. Pediatrics 97(2), 251-253 (1996).
31. Watson B. Varicella: a vaccine preventable disease? J. Infect. 44(4), 220-225 (2002).
32. Arvin AM, Gershon AA. Live-attenuated varicella vaccine. Ann. Rev. Microbiol. 50(5), 9-100 (1996).
33. Arvin AM. Varicella vaccine - the first 6 years. N. Engl. J. Med. 344(13), 1007-1009 (2001).
34. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am. J. Epidemiol. 140(8), 1-104 (1994).
35. Halloran ME. Epidemiologic effects of varicella vaccination. Infect. Dis. Clin. Nortb Am. 10(3), 631-655 (1996).
36. Seward J. Varicella updates. 37th National Immunization Conference. Chicago, IL, USA, 17-20 March 2003.
37. Zimmerman L, Fajardo M, Seward J, Ludwig S, Johnson J, Wharton M. Varicella susceptibility and validity of history among US Coast Guard recruits: an outbreak-based study. Mil. Med. 168(5), 404-407 (2003).
38. Izurieta H, Strebel P, Blake P. Postlicensure effectiveness of varicella vaccine during an outbreak in a childcare center. J. Am. Med. Assoc. 278(18), 1495-1499 (1997).
39. Buchholz U, Moolenaar R, Peterson C, Mascola L. Varicella outbreaks after vaccine licensure: should they make you chicken? Pediatrics 104(3 Pt 1), 561-563 (1999).
40. Galil K, Fair E, Mountcastle N, Britz P, Seward J. Younger age at vaccination may increase risk of varicella vaccine failure. J. Infect. Dis. 186(1), 102-105 (2002).
41. Dworkin MS, Jennings CE, Roth-Thomas J, Lang JE, Stukenberg C, Lumpkin JR. An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin. Infect. Dis. 35(1),102-104 (2002).
42. Berrios-Torres SI, Raymond D, Yeung LF, Blythe D, Jumaan AO, Ching P. Evaluation of varicella-zoster virus (VZV) vaccine effectiveness in an elementary school outbreak. 39th Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA, USA, 25-28 October 2001 (Abstract 377).
43. Galil K, Lee B, Strine T et al. Outbreak of varicella at a daycare center despite vaccination. N. Engl. J. Med. 347(24), 1909-1915 (2002).
44. Heath K, Watson B, Perella D, Robinson D, Jumaan A. 36th National Immunization Conference. Denver, CO, USA, 29 April-2 May 2002.
45. Tabony L, Kilgore P, Pelosi J et al. Varicella vaccine effectiveness during a childcare center outbreak, Travis Country TX, 1998. 35th Annual Meeting of the Infectious Diseases Society of America. Denver, CO, USA, 12-15 November 1998 (Abstract 79).
46. Simultaneous administration of varicella vaccine and other recommended childhood vaccines - United States. Morb. Mortal. Wkly Rep. 50(47), 1058-1061 (2001).
47. Seward JF. Update on varicella. Pediatr. Infect. Dis. J. 20(6), 619-621 (2001).
48. Watson B, Seward J, Yang A et al. Postexposure effectiveness of varicella vaccine. Pediatrics 105(1 Pt 1), 84-88 (2000).
49. Hall S, Galil K, Watson B, Seward J. The use of school-based vaccination clinics to control varicella outbreaks in two schools. Pediatrics 105(1), E17 (2000).
50. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. J. Am. Med. Assoc. 292(6), 704-708 (2004).
51. Watson B, Perella D, Heath K et al. Laboratory confirmation of suspected breakthrough varicella infections. Pediatric Academic Societies' Annual Meeting. San Francisco, CA, USA, 1-4 May 2004 (Abstract 1927).
52. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. Morb. Mortal. Wkly Rep. 46(RR-10), 1-55 (1997).
53. Shields KE, Galil K, Seward J, Sharrar RG, Cordero JF, Slater E. Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry. Obstet. Gynecol. 98(1), 14-19 (2001).
54. Gershon AA, Steinberg S, Gelb L et al. Live-attenuated varicella vaccine: efficacy for children with leukemia in remission. J. Am. Med. Assoc. 252(3), 355-362 (1984).
55. Asano Y, Suga S, Yoshikawa T et al. Experience and reason: 20-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94, 524-526 (1994).
56. Johnson C, Stancin T, Fattlar D, Rome LP, Kumar ML. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 100(5), 761-766 (1997).
57. Zerboni L, Nader S, Aoki K, Arvin AM. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J. Infect. Dis. 177(6), 1701-1704 (1998).
58. Clements DA, Armstrong CB, Ursano AM, Moggio M, Walter EB, Wilfert CM. Over 5-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr. Infect. Dis. J. 14(10), 874-879 (1995).
59. Gershon AA. Live-attenuated varicella vaccine. InfTect. Clin. North Am. 15(1), 65-81 (2001).
60. Watson B, Gupta R, Randall T et al. Persistence of cell-mediated and humoral immune responses in healthy children immunized with the live-attenuated varicella vaccine. J. Infect. Dis. 169(1), 197-199 (1994).
61. Mammano K, James D, James AI. Varicella susceptibility among women attending prenatal clinics in Philadelphia. 37th National Immunization Conference. Chicago, IL, USA, 17-20 March 2003 (Abstract 2087).
62. White CJ, Stinson D, Staehle B et al. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group. Clin. Infect. Dis. 24(5), 925-931 (1997).
63. Watson B, Rothstein E, Bernstein H et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J. Infect. Dis. 172(1), 217-219 (1995).
64. Watson BM, Laufer DS, Kuter BJ, Staehle B. White CJ, Starr SE. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR[II]V) in healthy children. J. Infect. Dis. 173(3), 731-734 (1996).
65. Guess HA, Broughton DD, Melton LJ 3rd, Kurland LT. Epidemiology of herpes-zoster in children and adolescents: a population-based study. Pediatrics 76(4), 512-517 (1985).
66. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N. Engl. J. Med. 325 (22), 1545-1550 (1991).
67. Levin DL, Hayward AR. Decreased herpetic neuralgia in patients immunized with varicella vaccine. 2nd International Conference for Varicella-Zoster Virus. Paris, Frace, 6-8 July 1995.
68. Levin MJ, Smith JG, Kaufhold RM et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J. Infec. Dis. 188(9), 1336-1344 (2003).
69. Watson B, Levin M. Varicella. Immunizing children against varicella: where are we now and what comes next. Contemp. Pediatr. (Suppl.) (2004).
70. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 20(7-8), 1113-1125 (2002).
71. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes-zoster in adults: a case-control study. Lancet 360(9334), 678-682 (2002).
72. Gershon AA, LaRussa P, Steinberg S, Mervish N, Lo SH, Meier P. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J. Infect. Dis. 173(2), 450-453 (1996).
73. Krause PR, Klinman DM. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nature Med. 6(4), 451-454 (2000).
74. Gershon AA. Varicella vaccine - are two doses better than one? N. Engl. J. Med. 347(24), 1962-1963 (2002).
75. Levin MJ, Smith JG, Kaufhold RM et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J. Infect. Dis. 188(9), 1336-1344 (2003).